AstraZeneca ‘Playing To Win’ With Cardiometabolic Combinations
The UK-based company is playing catch up in obesity, but believes it has a unique offering in a three-in-one therapy now moving into Phase II.
The UK-based company is playing catch up in obesity, but believes it has a unique offering in a three-in-one therapy now moving into Phase II.